DermTech Inc. (NASDAQ:DMTK) does about 742.24K shares in volume on a normal day but saw 410281 shares change hands in Friday trading. The company now has a market cap of 155.37M USD. Its current market price is $4.86, marking a decrease of -3.76% compared to the previous close of $5.05. The 52 week high reached by this stock is $16.33 whilst the lowest price level in 52 weeks is $1.55. The script in recent trading has seen the stock touch a high of $5.1316 and a low of $4.81.
DermTech Inc. (DMTK) has a 20-day trading average at $5.49 and the current price is -70.24% off the 52-week high compared with 213.55% distance from its 52-week low. The 50-day simple moving average of the closing price is $3.74 and its 200-day simple moving average is $4.84. If we look at the stock’s price movements over the week, volatility stands at 10.96%, which increases to 12.61% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 49.84 to suggest the stock is neutral.
The consensus objective for the share price is $7.83, suggesting that the stock has a potential upside of 37.93% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on July 18, 2022 when Oppenheimer resumed the stock to “Outperform” and issued a price target of $48. Stephens initiated its price target at $26.
The current price level is -11.20%, 31.58%, and -0.05% away from its SMA20, SMA50, and SMA200 respectively, with the DMTK price moving below the 50-day SMA on February 17. DermTech Inc. (DMTK) stock is down -11.96% over the week and 11.98% over the past month. Its price is 174.58% year-to-date and -64.76% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/29/2022, with the company’s earnings per share (EPS) of -$0.96 below consensus estimates by -$0.01. DMTK’s earnings per share are forecast to shrink by -44.60% this year and 5.60% over next year. Expected sales for next quarter are $3.68 million, which analysts say will come at $14.08 million for the current fiscal year and next year at $19.57 million. In addition, estimates put the company’s current quarterly revenue at an average of $2.56 million.
To reach the target analysts have set, the stock logically needs to grow 37.93 percent from here.
Outstanding shares total 30.10M with insiders holding 8.19% of the shares and institutional holders owning 40.15% of the company’s common stock. The company has a return on investment of -33.70% and return on equity of -59.70%. The beta has a value of 2.13. Price to book ratio is 0.94 and price to sales ratio is 10.57.
According to a U.S. Securities and Exchange Commission filing, Vanguard Total Stock Market Index has added its position in DermTech Inc. (DMTK) to 660,489 shares, mirroring a recent increase by 23.51%. Vanguard Total Stock Market Index added 0.13 million shares of DermTech Inc. common stock bringing its total worth to about $3.57 million at the end of recent close, SEC documents show. Fidelity Extended Market Index Fu cut their holdings by -0.41% in the company over the course of the most recent quarter. It now holds a 0.47% position in DermTech Inc. thanks to 0.14 million shares amounting to $0.76 million.
